The blood test that detects specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma (EAC) in your patients with chronic reflux.
A non-invasive assessment of EAC risk.
EAC rule out (NPV) of 99.9% enables doctors to confidently manage reflux.
EAC rule in (Sensitivity) of 91.4% guides treatment decisions.
How the PromarkerEso test works
Blood Sample
A sample is drawn at clinic or pathology laboratory.
Biomarker Analysis
Laboratory uses the technique of liquid-chromatography-mass spectrometry (LC-MS) to measure serum glycoprotein biomarkers.
PromarkerEso Hub
A software tool combines biomarkers with clinical factors in a proprietary algorithm to calculate the risk score.
Clinical Management
Provides physician confidence to manage reflux without EAC concern (Low Risk), or guide interventions (Moderate/High Risk).
Find out how PromarkerEso can make a difference
Learn more about this blood test that detects specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma in your patient suffering from chronic reflux.
